The FDA Finally Wrote Down How to Blind a Trial When the Drug Makes You Trip

You cannot easily hide from a research participant that they just took MDMA. That single, almost embarrassingly obvious problem — called “functional unblinding” in the FDA’s language — is what a divided advisory panel cited when it recommended against Lykos Therapeutics’ MDMA-assisted therapy for PTSD in 2024, and what the agency formally rejected the application over months later. This week, the FDA finally wrote down, in finalized clinical trial guidance, exactly what it wants sponsors to do about it.

A drug that makes the placebo group obvious isn’t un-testable. It just needed a regulator willing to say so in writing.

The guidance covers the whole class the FDA calls 5-HT2 agonists — psilocybin, LSD — plus MDMA, and it lays out specific fixes instead of just naming the problem: active placebos (a drug that produces some noticeable effect, rather than an inert sugar pill, so participants can’t simply guess their assignment from the absence of any sensation), blinding-adherence questionnaires that check whether the blind actually held, expectancy controls that account for how much a participant’s belief about what they took shapes their reported outcome, and — the most structurally interesting piece — a paired trial design that runs a placebo-controlled study alongside a separate dose-response study with no placebo arm at all, so a sponsor can triangulate efficacy even where blinding is functionally impossible. Jefferies told investors the final guidance “suggests the agency remains receptive to helping sponsors succeed” — market-speak for: this is the FDA choosing to build a path through the problem instead of using it as a permanent gate against the whole drug class.

The agency also announced a public hearing for September 14, open both in person and virtually, to gather broader input on how psychedelic drugs might eventually be used in “supervised and supportive settings” — language that matters, because it’s the FDA drawing an explicit line between a clinic-administered therapy and anything resembling unsupervised use. For treatment providers watching this space because a patient asked about it: this guidance does not mean psilocybin or MDMA therapy is available, approved, or legal outside a clinical trial anywhere in the country right now. It means the specific procedural obstacle that killed the last major application in this category now has an official, written-down answer, which is a real and separate thing from availability. If a patient brings this up at your next intake, that’s the distinction worth having ready — the science just moved forward; the door to your office didn’t open yet.